首页> 外文期刊>Medicine. >Ultrasonography-Guided Core Biopsy of Supraclavicular Lymph Nodes for Diagnosis of Metastasis and Identification of Epidermal Growth Factor Receptor (EGFR) Mutation in Advanced Lung Cancer
【24h】

Ultrasonography-Guided Core Biopsy of Supraclavicular Lymph Nodes for Diagnosis of Metastasis and Identification of Epidermal Growth Factor Receptor (EGFR) Mutation in Advanced Lung Cancer

机译:超声引导下锁骨上淋巴结的核心活检对晚期肺癌的转移和表皮生长因子受体(EGFR)突变的诊断和鉴定

获取原文
获取外文期刊封面目录资料

摘要

The aim of this study was to evaluate the diagnostic performance of ultrasonography (US)-guided core biopsy of a supraclavicular lymph node (SCN) for detecting metastasis and epidermal growth factor receptor (EGFR) mutations. We included 229 patients who underwent US-guided core biopsy of SCN with lung cancer from January 2011 to December 2013. We evaluated the morphologic characteristics and measured the sizes of SCNs on US and chest computed tomography (CT). The clinical stage, maximum standardized uptake value (SUVmax) on 18F-fluorodeoxyglucose positron emission tomography, and the morphology on US and CT in the positive metastasis were compared with those in the negative metastasis. The prevalence of EGFR mutations of the adenocarcinoma and procedure-related complication was investigated. The accuracy of US-guided core biopsy of SCN diagnosing metastasis was 97.8% (224/229). The cutoff values (sensitivity; specificity; area under the receiver operating characteristic curve, 95% confidence interval [CI]) of the short-axis dimension of SCN on CT were 0.85 cm (72.3%; 80.6%; 0.808, 95% CI: 0.740–0.875), on US 0.75 cm (73.5%; 84.8%; 0.843, 95% CI: 0.788–0.897), and that of SUVmax 4.05 (79.1%; 81.8%; 0.853, 95% CI: 0.780–0.925). The mutations were positive in 35.8% with adenocarcinoma. There were no procedure-related complications of US-guided SCN core biopsy. US-guided SCN core biopsy is a reliable and safe method for detecting metastasis, histologic subtyping, and identifying the EGFR mutation in the advanced lung cancers. It may be a substitute for more invasive lung biopsy as an initial tissue confirmation in the advanced disease.
机译:这项研究的目的是评估超声检查(US)引导的锁骨上淋巴结(SCN)的核心活检对转移和表皮生长因子受体(EGFR)突变的诊断性能。我们纳入了从2011年1月至2013年12月接受美国指导的肺癌SCN活检的229例患者。我们评估了其形态特征,并在美国和胸部CT上测量了SCN的大小。临床阶段,18F-氟脱氧葡萄糖正电子发射断层显像的最大标准摄取值(SUV max )及其形态将US和CT阳性转移与阴性转移进行比较。研究了腺癌的EGFR突变患病率和与手术相关的并发症。美国指导的SCN诊断转移活检的准确性为97.8%(224/229)。 CT上SCN短轴尺寸的临界值(敏感性;特异性;受体工作特征曲线下的面积,95%置信区间[CI])为0.85 cm(72.3%; 80.6%; 0.808,95%CI: 0.740–0.875),美国0.75厘米(73.5%; 84.8%; 0.843、95%CI:0.788–0.897)和SUV 最大 4.05(79.1%; 81.8%; 0.853,95%CI:0.780–0.925)。腺癌中35.8%的突变为阳性。美国指导的SCN核心活检没有与手术相关的并发症。美国指导的SCN核心活检是一种检测晚期肺癌转移,组织学亚型和鉴定EGFR突变的可靠且安全的方法。它可以代替更具侵入性的肺活检作为晚期疾病的初始组织确认。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号